InMed Pharmaceutical’s (IN.T) IntegraSyn™ cannabinoid manufacturing approach has achieved a level of 2 grams per liter (g/L), marking a significant milestone for the commercialization of IntegraSyn™. “We are very…
InMed
Inmed Pharmaceuticals (IN.T) filed a patent co-operation treaty (PCT) application relating to the potential for cannabinoids to prevent neuron damage associated with glaucoma. The patent application is called “Compositions…
It’s been a while since Emblem Cannabis (EMC.V) hit the public markets as one of the big five, making early investors who bought in at $1.15 per share wealthy…